Class information for: |
Basic class information |
Class id | #P | Avg. number of references |
Database coverage of references |
---|---|---|---|
2449 | 2241 | 29.5 | 75% |
Hierarchy of classes |
The table includes all classes above and classes immediately below the current class. |
Cluster id | Level | Cluster label | #P |
---|---|---|---|
6 | 4 | GASTROENTEROLOGY & HEPATOLOGY//ONCOLOGY//SURGERY | 1371034 |
139 | 3 | THYROID//THYROID CANCER//GRAVES DISEASE | 64904 |
301 | 2 | THYROID CANCER//THYROID NODULE//PAPILLARY THYROID CARCINOMA | 18583 |
2449 | 1 | THYROGLOBULIN//DIFFERENTIATED THYROID CANCER//DIFFERENTIATED THYROID CARCINOMA | 2241 |
Terms with highest relevance score |
rank | Term | termType | Chi square | Shr. of publ. in class containing term |
Class's shr. of term's tot. occurrences |
#P with term in class |
---|---|---|---|---|---|---|
1 | THYROGLOBULIN | authKW | 1201637 | 12% | 34% | 263 |
2 | DIFFERENTIATED THYROID CANCER | authKW | 961573 | 7% | 43% | 164 |
3 | DIFFERENTIATED THYROID CARCINOMA | authKW | 857271 | 6% | 45% | 139 |
4 | THYROID CANCER | authKW | 665916 | 16% | 13% | 366 |
5 | RADIOIODINE | authKW | 478817 | 6% | 27% | 128 |
6 | RHTSH | authKW | 447029 | 2% | 75% | 44 |
7 | RADIOIODINE THERAPY | authKW | 434715 | 5% | 29% | 111 |
8 | RECOMBINANT HUMAN THYROID STIMULATING HORMONE | authKW | 306987 | 1% | 87% | 26 |
9 | WHOLE BODY SCAN | authKW | 297133 | 2% | 64% | 34 |
10 | RECOMBINANT HUMAN TSH | authKW | 273861 | 1% | 72% | 28 |
Web of Science journal categories |
Rank | Term | Chi square | Shr. of publ. in class containing term |
Class's shr. of term's tot. occurrences |
#P with term in class |
---|---|---|---|---|---|
1 | Radiology, Nuclear Medicine & Medical Imaging | 22311 | 39% | 0% | 869 |
2 | Endocrinology & Metabolism | 15335 | 32% | 0% | 722 |
3 | Medical Laboratory Technology | 832 | 3% | 0% | 77 |
4 | Oncology | 577 | 10% | 0% | 231 |
5 | Otorhinolaryngology | 239 | 3% | 0% | 58 |
6 | Medicine, General & Internal | 166 | 6% | 0% | 128 |
7 | Medicine, Research & Experimental | 54 | 3% | 0% | 69 |
8 | Surgery | 35 | 5% | 0% | 102 |
9 | Pathology | 2 | 1% | 0% | 23 |
10 | Dentistry, Oral Surgery & Medicine | 0 | 1% | 0% | 15 |
Address terms |
Rank | Term | Chi square | Shr. of publ. in class containing term |
Class's shr. of term's tot. occurrences |
#P with term in class |
---|---|---|---|---|---|
1 | NUCL MED | 181066 | 33% | 2% | 744 |
2 | INTERNAL MED ENDOCRINOL METAB BIOCHEM | 58929 | 1% | 29% | 15 |
3 | THYROID UNIT | 51614 | 1% | 12% | 32 |
4 | NUCL MED SERV | 44055 | 4% | 3% | 100 |
5 | MEM HOSP CANC ALLIED DIS | 43595 | 0% | 80% | 4 |
6 | MED EO | 40872 | 0% | 100% | 3 |
7 | NUCL MED THYROID | 34055 | 0% | 50% | 5 |
8 | SERV ENDOCRINOL | 28398 | 4% | 3% | 79 |
9 | GENET MOL CANC ENDOCRINOL | 27248 | 0% | 100% | 2 |
10 | LAURENT ALBERTA GER EL PET | 27248 | 0% | 100% | 2 |
Journals |
Rank | Term | Chi square | Shr. of publ. in class containing term |
Class's shr. of term's tot. occurrences |
#P with term in class |
---|---|---|---|---|---|
1 | THYROID | 149681 | 9% | 5% | 201 |
2 | CLINICAL NUCLEAR MEDICINE | 50606 | 7% | 2% | 157 |
3 | NUKLEARMEDIZIN-NUCLEAR MEDICINE | 40737 | 3% | 5% | 59 |
4 | JOURNAL OF NUCLEAR MEDICINE | 36882 | 7% | 2% | 166 |
5 | NUCLEAR MEDICINE COMMUNICATIONS | 33405 | 5% | 2% | 101 |
6 | EUROPEAN JOURNAL OF NUCLEAR MEDICINE AND MOLECULAR IMAGING | 22610 | 3% | 2% | 73 |
7 | QUARTERLY JOURNAL OF NUCLEAR MEDICINE AND MOLECULAR IMAGING | 19727 | 1% | 5% | 28 |
8 | ANNALS OF NUCLEAR MEDICINE | 17067 | 2% | 3% | 49 |
9 | JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM | 11782 | 6% | 1% | 144 |
10 | CLINICAL ENDOCRINOLOGY | 7599 | 3% | 1% | 65 |
Author Key Words |
Rank | Term | Chi square | Shr. of publ. in class containing term |
Class's shr. of term's tot. occurrences |
#P with term in class |
LCSH search | Wikipedia search |
---|---|---|---|---|---|---|---|
1 | THYROGLOBULIN | 1201637 | 12% | 34% | 263 | Search THYROGLOBULIN | Search THYROGLOBULIN |
2 | DIFFERENTIATED THYROID CANCER | 961573 | 7% | 43% | 164 | Search DIFFERENTIATED+THYROID+CANCER | Search DIFFERENTIATED+THYROID+CANCER |
3 | DIFFERENTIATED THYROID CARCINOMA | 857271 | 6% | 45% | 139 | Search DIFFERENTIATED+THYROID+CARCINOMA | Search DIFFERENTIATED+THYROID+CARCINOMA |
4 | THYROID CANCER | 665916 | 16% | 13% | 366 | Search THYROID+CANCER | Search THYROID+CANCER |
5 | RADIOIODINE | 478817 | 6% | 27% | 128 | Search RADIOIODINE | Search RADIOIODINE |
6 | RHTSH | 447029 | 2% | 75% | 44 | Search RHTSH | Search RHTSH |
7 | RADIOIODINE THERAPY | 434715 | 5% | 29% | 111 | Search RADIOIODINE+THERAPY | Search RADIOIODINE+THERAPY |
8 | RECOMBINANT HUMAN THYROID STIMULATING HORMONE | 306987 | 1% | 87% | 26 | Search RECOMBINANT+HUMAN+THYROID+STIMULATING+HORMONE | Search RECOMBINANT+HUMAN+THYROID+STIMULATING+HORMONE |
9 | WHOLE BODY SCAN | 297133 | 2% | 64% | 34 | Search WHOLE+BODY+SCAN | Search WHOLE+BODY+SCAN |
10 | RECOMBINANT HUMAN TSH | 273861 | 1% | 72% | 28 | Search RECOMBINANT+HUMAN+TSH | Search RECOMBINANT+HUMAN+TSH |
Core articles |
The table includes core articles in the class. The following variables is taken into account for the relevance score of an article in a cluster c: (1) Number of references referring to publications in the class. (2) Share of total number of active references referring to publications in the class. (3) Age of the article. New articles get higher score than old articles. (4) Citation rate, normalized to year. |
Rank | Reference | # ref. in cl. |
Shr. of ref. in cl. |
Citations |
---|---|---|---|---|
1 | BUTON, L , MOREL, O , GAULT, P , ILLOUZ, F , RODIEN, P , ROHMER, V , (2013) FALSE-POSITIVE IODINE-131 WHOLE-BODY SCAN FINDINGS IN PATIENTS WITH DIFFERENTIATED THYROID CARCINOMA: REPORT OF 11 CASES AND REVIEW OF THE LITERATURE.ANNALES D ENDOCRINOLOGIE. VOL. 74. ISSUE 3. P. 221-230 | 94 | 95% | 6 |
2 | EUSTATIA-RUTTEN, CFA , SMIT, JWA , ROMIJN, JA , VAN DER KLEIJ-CORSSMIT, EPM , PEREIRA, AM , STOKKEL, MP , KIEVIT, J , (2004) DIAGNOSTIC VALUE OF SERUM THYROGLOBULIN MEASUREMENTS IN THE FOLLOW-UP OF DIFFERENTIATED THYROID CARCINOMA, A STRUCTURED META-ANALYSIS.CLINICAL ENDOCRINOLOGY. VOL. 61. ISSUE 1. P. 61-74 | 102 | 81% | 79 |
3 | TRIGGIANI, V , GIAGULLI, VA , IOVINO, M , DE PERGOLA, G , LICCHELLI, B , VARRASO, A , DICEMBRINO, F , VALLE, G , GUASTAMACCHIA, E , (2016) FALSE POSITIVE DIAGNOSIS ON (131)IODINE WHOLE-BODY SCINTIGRAPHY OF DIFFERENTIATED THYROID CANCERS.ENDOCRINE. VOL. 53. ISSUE 3. P. 626 -635 | 74 | 91% | 0 |
4 | FARD-ESFAHANI, A , EMAMI-ARDEKANI, A , FALLAHI, B , FARD-ESFAHANI, P , BEIKI, D , HASSANZADEH-RAD, A , EFTEKHARI, M , (2014) ADVERSE EFFECTS OF RADIOACTIVE IODINE-131 TREATMENT FOR DIFFERENTIATED THYROID CARCINOMA.NUCLEAR MEDICINE COMMUNICATIONS. VOL. 35. ISSUE 8. P. 808 -817 | 82 | 69% | 9 |
5 | CLARK, PM , CHIOVATO, L , DUNTAS, L , ELISEI, R , FELDT-RASMUSSEN, U , LEENHARDT, L , LUSTER, M , SCHALIN-JANTTI, C , SCHOTT, M , SEREGNI, E , ET AL (2014) DIAGNOSIS OF ENDOCRINE DISEASE THYROGLOBULIN MEASUREMENT USING HIGHLY SENSITIVE ASSAYS IN PATIENTS WITH DIFFERENTIATED THYROID CANCER: A CLINICAL POSITION PAPER.EUROPEAN JOURNAL OF ENDOCRINOLOGY. VOL. 171. ISSUE 2. P. R33 -R46 | 55 | 92% | 17 |
6 | VERBURG, FA , LUSTER, M , CUPINI, C , CHIOVATO, L , DUNTAS, L , ELISEI, R , FELDT-RASMUSSEN, U , RIMMELE, H , SEREGNI, E , SMIT, JWA , ET AL (2013) IMPLICATIONS OF THYROGLOBULIN ANTIBODY POSITIVITY IN PATIENTS WITH DIFFERENTIATED THYROID CANCER: A CLINICAL POSITION STATEMENT.THYROID. VOL. 23. ISSUE 10. P. 1211 -1225 | 74 | 68% | 30 |
7 | ZANOTTI-FREGONARA, P , TOUBERT, ME , TAIEB, D , RAVASI, L , RUBELLO, D , HINDIE, E , (2008) OVERVIEW ON THE USE OF RECOMBINANT HUMAN THYROTROPIN IN THYROID CANCER OF FOLLICULAR CELL ORIGIN.MINERVA ENDOCRINOLOGICA. VOL. 33. ISSUE 2. P. 53 -65 | 75 | 87% | 5 |
8 | GRAMZA, A , SCHUFF, KG , (2008) RECOMBINANT HUMAN THYROID STIMULATING HORMONE IN 2008: FOCUS ON THYROID CANCER MANAGEMENT.ONCOTARGETS AND THERAPY. VOL. 1. ISSUE . P. 87 -101 | 71 | 92% | 3 |
9 | CARLISLE, MR , LU, C , MCDOUGALL, IR , (2003) THE INTERPRETATION OF I-131 SCANS IN THE EVALUATION OF THYROID CANCER, WITH AN EMPHASIS ON FALSE POSITIVE FINDINGS.NUCLEAR MEDICINE COMMUNICATIONS. VOL. 24. ISSUE 6. P. 715-735 | 77 | 91% | 53 |
10 | LOPRESTI, J , FATEMI, S , SPENCER, C , (2014) HOW SENSITIVE (SECOND-GENERATION) THYROGLOBULIN MEASUREMENT IS CHANGING PARADIGMS FOR MONITORING PATIENTS WITH DIFFERENTIATED THYROID CANCER, IN THE ABSENCE OR PRESENCE OF THYROGLOBULIN AUTOANTIBODIES.CURRENT OPINION IN ENDOCRINOLOGY DIABETES AND OBESITY. VOL. 21. ISSUE 5. P. 394 -404 | 69 | 73% | 7 |
Classes with closest relation at Level 1 |